Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study

por Sherman, E., Lee, J.L., Debruyne, P.R., Keam, B., Shin, S.J., Gramza, A., Caro, I., Amin, R., Shah, K., Yan, Y., Huddart, R., Powles, T.
Publicado 2023

Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma

por Lee, J.-K., Louzada, S., An, Y., Kim, S. Y., Kim, S., Youk, J., Park, S., Koo, S. H., Keam, B., Jeon, Y. K., Ku, J.-L., Yang, F., Kim, T. M., Ju, Y. S.
Publicado 2017

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

por Kim, M., Lee, J.L., Shin, S.J., Bae, W.K., Lee, H.J., Byun, J.H., Choi, Y.J., Youk, J., Ock, C.Y., Kim, S., Song, H., Park, K.H., Keam, B.
Publicado 2023

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

por Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., Ilankumaran, P., Burgess, P., Romero Salas, T., Keam, B.
Publicado 2022

Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck...

por Keam, B., Machiels, J.-P., Kim, H.R., Licitra, L., Golusinski, W., Gregoire, V., Lee, Y.G., Belka, C., Guo, Y., Rajappa, S.J., Tahara, M., Azrif, M., Ang, M.K., Yang, M.-H., Wang, C.-H., Ng, Q.S., Wan Zamaniah, W.I., Kiyota, N., Babu, S., Yang, K., Curigliano, G., Peters, S., Kim, T.W., Yoshino, T., Pentheroudakis, G.
Publicado 2021